Results 121 to 130 of about 9,514 (200)

Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach. [PDF]

Cancers (Basel)
Santambrogio E, Castellino A, Audisio E, Schumacher M, Feldmann G, Iftikhar R, Brossart P, Aydin S.   +7 more
europepmc   +1 more source

A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents. [PDF]

Cancer
Peters DT, Zeidner JF.
europepmc   +1 more source

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia. [PDF]

Leukemia
Li YR, Shen X, Chen Y, Zhu Y, Huang J, Oliai C, Yang L.   +6 more
europepmc   +1 more source

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study. [PDF]

Front Pharmacol
Tian JX, Zhang P, Wang XX, Li JW, Liu DX, Liu YY, Xiao ZJ, Miao WJ.   +7 more
europepmc   +1 more source

Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review. [PDF]

Front Oncol
Mi R, Guo S, Yang W, Wang L, Ma Y, Chen L, Li D, Wei X.   +7 more
europepmc   +1 more source

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia. [PDF]

Haematologica
Verdeyen K, Reuvekamp T, Van der Velden WJFM, Wouters BJ, Von dem Borne PA, Van Rhenen A, Lissenberg-Witte BI, Van Lammeren D, Van Sluis GL, De Jongh E, Fiets RB, Corsten MF, Van der Spek AC, Gerrits AM, Van Bladel ER, Tick LW, De Weerdt O, Van Zaane B, Cruijsen MJ, Posthuma EFM, Van Elssen CHMJ, Klein SK, Van de Loosdrecht AA, De Leeuw DC.   +23 more
europepmc   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. [PDF]

Blood Neoplasia
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA.   +9 more
europepmc   +1 more source

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States. [PDF]

Blood Neoplasia
Mukherjee S, Dong W, Gerds AT, Carraway HE, Singh A, Advani AS, Mustafa Ali MK, Molina JC, Balderman S, Jain A, Caimi P, Anwer F, Sekeres MA, Koroukian SM.   +13 more
europepmc   +1 more source

Corrigendum to "Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification" [Leukemia Research Reports 24 (2025) 100550]. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source